Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Medical education · Dr. Paola Castellano

16 Feb 2026 · In person · Dr. Paola Castellano, Vall d'Hebron · MSL James Whitfield · Vantrexa

ReviewedManualENG-0094MI request

Capture insight from this engagement

Location: Hospital La Paz
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response
Sequencing after progression

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

How should grade 2 infusion reactions be managed without steroids?
What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Medical education with radiation oncologist at Hospital La Paz. Discussed duration of response, sequencing after progression.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 5
Actionability: 3

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0094

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
02 Sept 2026, 13:53 UTC	Update	FAFatima Al-Sayed	dueDate	In progress → Submitted	—	Integration